<DOC>
	<DOCNO>NCT02358031</DOCNO>
	<brief_summary>Participants recurrent metastatic ( R/M ) squamous cell cancer head neck ( HNSCC ) randomly assign receive pembrolizumab alone , pembrolizumab + platinum-based drug ( cisplatin carboplatin ) + 5-Fluorouracil ( 5-FU ) , cetuximab + platinum-based drug ( cisplatin carboplatin ) + 5-FU . The primary study hypothesis pembrolizumab pembrolizumab combination chemotherapy prolongs progression free survival overall survival compare standard treatment .</brief_summary>
	<brief_title>A Study Pembrolizumab ( MK-3475 ) First Line Treatment Recurrent Metastatic Squamous Cell Cancer Head Neck ( MK-3475-048/KEYNOTE-048 )</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologicallyconfirmed recurrent metastatic head neck squamous cell carcinoma consider incurable local therapy No prior systemic therapy administer recurrent metastatic setting ( exception systemic therapy complete &gt; 6 month prior give part multimodal treatment locally advanced disease ) Primary tumor location oropharynx , oral cavity , hypopharynx , larynx . Participants may primary tumor site nasopharynx ( histology ) Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Can provide tissue PDL1 biomarker analysis core excisional biopsy ( fine needle aspirate sufficient ) : A newly obtain biopsy ( within 90 day prior start study treatment ) prefer archival sample acceptable . Have result test HPV status oropharyngeal cancer Female participant childbearing potential negative pregnancy test must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 180 day last dose study medication Male participant must agree use adequate method contraception start first dose study medication 180 day last dose study medication Disease suitable local therapy administer curative intent Has progressive disease ( PD ) within six ( 6 ) month completion curatively intended systemic treatment locoregionally advance HNSCC Radiation therapy ( nonsystemic therapy ) within 2 week prior randomization fully recovered adverse event due previously administer treatment Currently participate receive study therapy , participate study investigational agent receive study therapy , use investigational device within 4 week first dose study medication Life expectancy &lt; 3 month and/or rapidly progress disease Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication ( physiologic dos corticosteroid may approve consultation Sponsor ) Diagnosed and/or treat additional malignancy within 5 year prior randomization exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin and/or curatively resect situ cervical and/or breast cancer Has allogeneic tissue/solid organ transplant Active central nervous system metastases and/or carcinomatous meningitis Active autoimmune disease require systemic treatment past 2 year ; replacement therapy consider form systemic treatment History ( noninfectious ) pneumonitis require steroid current pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement trial Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 180 day last dose study medication Prior therapy antiPD1 , antiPDL1 , antiPDL2 agent previously participate Merck MK3475 clinical trial Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B C Received live vaccine within 30 day plan start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
</DOC>